-

 

Fertility: Avoiding Medicines That Negatively Impact Conception

Abstract

Declining fertility rates and increasing reproductive health disorders have become significant global public health concerns. While attention has often focused on lifestyle, nutrition, and environmental toxins, the role of commonly used medications in impairing conception remains under-addressed. This paper examines pharmaceuticals that negatively influence fertility in both women and men, explores biological mechanisms underlying reproductive disruption, and highlights compounded risks arising from environmental chemical exposures. It further evaluates regulatory gaps in low- and middle-income countries (LMICs), particularly in sub-Saharan Africa, where medication use is often poorly monitored. The paper concludes with policy and clinical recommendations aimed at safeguarding reproductive potential while maintaining access to essential medicines.

1. Introduction

Human fertility is a complex biological process influenced by endocrine signaling, metabolic health, genetics, and environmental exposures. Over the past two decades, global fertility rates have declined significantly, with emerging evidence linking this trend not only to sociocultural factors but also to pharmaceutical and chemical exposures (WHO, 2023).

In many African contexts, self-medication, over-the-counter drug access, and prolonged use of medications without fertility risk assessment have become common. Simultaneously, environmental contaminants such as plastics, pesticides, and heavy metals amplify pharmaceutical effects through endocrine disruption. This convergence presents a silent but growing threat to reproductive health.

2. Biological Pathways Through Which Medicines Affect Conception

Medicines may impair conception through several mechanisms:

2.1 Endocrine Disruption

Certain drugs interfere with estrogen, progesterone, testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), disrupting ovulation or spermatogenesis.

2.2 Gametotoxicity

Some pharmaceuticals directly damage oocytes or sperm cells, reducing viability, motility, or genetic integrity.

2.3 Hypothalamic–Pituitary–Gonadal (HPG) Axis Suppression

Drugs that suppress gonadotropin release interfere with reproductive signaling pathways.

2.4 Epigenetic Alterations

Emerging evidence suggests that some drugs induce heritable epigenetic modifications, potentially affecting fertility across generations.

3. Medicines That Negatively Affect Female Conception

3.1 Hormonal Agents

  • Hormonal contraceptives may delay ovulation resumption.

  • Gonadotropin-releasing hormone (GnRH) analogues suppress ovarian activity.

  • Danazol disrupts estrogen-progesterone balance.

3.2 Anti-inflammatory and Analgesic Drugs

  • Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac inhibit prostaglandin synthesis, impairing follicular rupture and ovulation.

3.3 Psychotropic and Neurological Drugs

  • Antipsychotics (e.g., risperidone) elevate prolactin levels, suppressing ovulation.

  • Valproate is strongly associated with polycystic ovarian morphology and endocrine dysfunction.

3.4 Cytotoxic and Immunosuppressive Agents

  • Methotrexate and cyclophosphamide cause ovarian follicle depletion and are linked to premature ovarian failure.

4. Medicines That Negatively Affect Male Conception

4.1 Hormonal Manipulators

  • Exogenous testosterone and anabolic steroids suppress endogenous sperm production.

  • Finasteride and dutasteride reduce sperm count and motility.

4.2 Antimicrobials and Chronic Therapies

  • Sulfasalazine, nitrofurantoin, and some macrolides impair sperm morphology and motility.

4.3 Antiepileptic and Psychiatric Medications

  • Valproate and carbamazepine reduce testosterone and impair spermatogenesis.

5. Interaction with Environmental and Chemical Exposures

Pharmaceutical impacts on fertility are often amplified by environmental exposures such as:

  • Endocrine-disrupting chemicals (EDCs): BPA, PFAS, phthalates

  • Agricultural pesticides: organophosphates, pyrethroids

  • Heavy metals: mercury, lead, cadmium

In low-resource settings, chronic low-dose exposure often goes unmonitored, leading to cumulative reproductive toxicity.

6. Public Health and Policy Gaps

6.1 Weak Pharmacovigilance Systems

Many LMICs lack reproductive toxicity surveillance for commonly prescribed medications.

6.2 Inadequate Labeling and Public Awareness

Drug inserts rarely highlight fertility risks in accessible language.

6.3 Unregulated Over-the-Counter Sales

Easy access to prescription medicines increases misuse and prolonged exposure.

6.4 Gendered Health Inequities

Women disproportionately bear fertility-related health consequences despite male-factor infertility contributing to nearly 50% of cases.

7. Policy Recommendations

7.1 Strengthen Regulatory Oversight

  • Mandatory fertility-impact labeling for high-risk medicines

  • Pre-authorization review for reproductive toxicity

7.2 Integrate Fertility Risk Assessment into Primary Care

  • Include fertility screening before long-term prescriptions

  • Train healthcare workers on medication–fertility interactions

7.3 Promote Safer Prescribing Practices

  • Encourage non-hormonal and non-gonadotoxic alternatives

  • Limit long-term NSAID use unless clinically justified

7.4 Environmental and Chemical Control

  • Regulate endocrine-disrupting chemicals in consumer products

  • Strengthen pesticide control policies

7.5 Public Education and Community Engagement

  • National awareness campaigns on fertility-safe medicine use

  • Target youth and reproductive-age populations

8. Implications for Africa and Low-Resource Settings

In regions such as sub-Saharan Africa, fertility remains culturally, socially, and economically significant. Medication-related infertility exacerbates stigma, gender inequality, and psychosocial distress. Preventive policy approaches are therefore essential to safeguard reproductive health and demographic stability.

9. Conclusion

Avoiding medicines that negatively impact conception is not merely a clinical concern but a public health and policy priority. Integrating fertility risk awareness into pharmaceutical governance, environmental regulation, and healthcare delivery systems is essential for protecting present and future generations. Proactive, evidence-based policy interventions can significantly reduce preventable infertility while preserving therapeutic access.

References (Selected)

  1. World Health Organization (2023). Infertility prevalence and trends.

  2. Skakkebaek, N. E. et al. (2022). Environmental factors in male reproductive health. Nature Reviews Endocrinology.

  3. Gore, A. C. et al. (2015). Endocrine-disrupting chemicals. Endocrine Reviews.

  4. Practice Committee of the American Society for Reproductive Medicine (2020). Medications and fertility.

  5. WHO & UNEP (2019). State of the science of endocrine disrupting chemicals.

  6. Joffe, M. (2017). Infertility and environmental exposures. Occupational Medicine.

Comments

Post a Comment

Popular posts from this blog

-
  Impacts of Pit Latrine Waste on Early Puberty in Africa Introduction Across sub-Saharan Africa, pit latrines serve as the primary sanitation infrastructure for over 50% of urban populations and an even higher proportion in rural areas, providing a low-cost solution to the challenge of open defecation. These simple, often unlined pits collect human waste but pose significant risks to environmental and public health due to potential groundwater contamination. Emerging evidence suggests that chemical pollutants from pit latrines, particularly endocrine-disrupting chemicals (EDCs), may contribute to early puberty in children, especially girls, with far-reaching health, social, and educational consequences. Early puberty, defined as pubertal development before age 8 in girls or 9 in boys, is associated with increased risks of mental health disorders, reproductive health issues, and socioeconomic challenges, particularly in resource-constrained settings. In Africa, where sanitation inf...
Read more
-
  Health insurance affordability and the quality of life among low Socioeconomic Status (SES) individuals in Low- and Middle-Income Countries (LMICs)   Preamble: Whereas the right to health is a fundamental human right, it remains inaccessible to many, especially those of low socioeconomic status (SES) in low- and middle-income countries (LMICs); and whereas the affordability of health insurance is a critical factor that can enhance or impede access to necessary healthcare services; we recognize that the ability to obtain health insurance plays a pivotal role in determining the quality of life for individuals and families within these communities. Acknowledging that the lack of affordable health insurance options leads to a disproportionate burden of disease and financial hardship on low SES populations; and understanding that the provision of affordable health insurance is not only a matter of social justice but also an investment in the social and economic development ...
Read more
-
Child Health:  Dealing with Aflatoxins in Children’s Food Aflatoxins, produced primarily by Aspergillus flavus and A. parasiticus , are highly toxic and carcinogenic mycotoxins that contaminate key food crops in tropical and subtropical regions. In low- and middle-income countries (LMICs), especially across sub-Saharan Africa, chronic exposure to aflatoxins in staple foods poses grave health risks for children, including growth impairment, immunosuppression, developmental deficits, and increased vulnerability to infectious diseases. This paper explores the sources of aflatoxin contamination in children's food, its public health impacts, and proposes multisectoral policies and interventions to protect child health and nutrition, with a focus on evidence from Africa. 1. Introduction Aflatoxin contamination is one of the most pressing yet under-addressed food safety challenges affecting children in LMICs. Staple foods such as maize, sorghum, groundnuts, and dairy products are pro...
Read more